Jump to content
Company database

Atriva Therapeutics GmbH

ATRIVA Therapeutics GmbH, an emerging antiviral biotech company, based in Tübingen, Germany, exploits the benefits of MEK-Inhibitors as powerful and broadly applicable antiviral drugs. MEK-Inhibitors, originally developed as cancer therapy, are blocking the intracellular kinase MEK, part of the Raf/MEK/ERK signaling pathway, which many RNA viruses need to replicate.

Eight experienced entrepreneurs and scientists founded ATRIVA in 2015 as a spin-off from the Universities Münster, Giessen and Tübingen. The lead project uses the scientific findings of three founders to develop a new class of treatment for severe influenza. ATRIVA already made substantial progress with the technology and the lead project as well as its project pipeline and has broadened its scope to other severe viral diseases including MERS, SARS (Coronavirus), Hantavirus (Bunyaviridae). Commonly, these viruses cause severe respiratory disease, often with fatal outcome, and no efficacious cure is yet available. MEK-Inhibitors are active against this variety of RNA viruses, as shown in several preclinical studies.

ATRIVA does not expect any resistance development, as the virus can- not reverse the blockade of the cellular signaling pathway. Relevant side effects within the intended antiviral use are unlikely, as 1) treatment dura- tion will not exceed 14 days, and 2) drug concentrations inhibiting viral replication are expected to be lower than those for anti-proliferative effects in tumor therapy, as shown in ATRIVA‘s extensive preclinical studies.

In essence, ATRIVA provides the technology for a completely novel anti-pathogen approach representing a paradigm change in therapy of severe respiratory infections.

Biotech CompaniesTherapeutics

Further information on the websites of BIOPRO Baden-Württemberg:

Website address: https://www.bio-pro.de/en/service/details